Tempus AI, Inc. Class A Common Stock (TEM) Stock
Key stats
- Market cap
- $11.75B
- Price / Earnings ratio
- -50.4x
- EPS (TTM)
- -$6.91
- Volume
- Loading
- 52-week high
- $97.25
- 52-week low
- $40.77
- EPS vs analyst estimate
- +56.0%Q3 FY25 · -$0.11 vs -$0.25
Source: third-party data provider, as of October 18, 2026
EPS estimate: analyst consensus
Compare with TEM
Recent news

Tempus to Report Third Quarter 2026 Financial Results on November 2
Tempus to Report Third Quarter 2026 Financial Results on November 2
TEM

Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
TEM

Tempus AI Expands Strategic Collaborations to Drive Future Growth
Tempus AI Expands Strategic Collaborations to Drive Future Growth
TEM

Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom?
Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom?
TEM
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 41.50
- MACD 12/26/9
- -0.36
- EMA 9 of MACD
- 1.46
- MACD histogram
- -1.82
- SMA 50
- $67.82
- Price below SMA 50
- EMA 50
- $67.88
- Price below EMA 50
- SMA 200
- $56.79
- Price above SMA 200
- EMA 200
- $62.57
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 16, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 13 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.27 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Tempus to Report Third Quarter 2026 Financial Results on November 2
Tempus to Report Third Quarter 2026 Financial Results on November 2
TEM

Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
TEM

Tempus AI Expands Strategic Collaborations to Drive Future Growth
Tempus AI Expands Strategic Collaborations to Drive Future Growth
TEM

Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom?
Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom?
TEM

Here's How Tempus AI is Capitalizing on AI-ECG Market Growth
Here's How Tempus AI is Capitalizing on AI-ECG Market Growth
TEM

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
TEM

Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
TEM

Tempus AI Chief Accounting Officer Sells $529,650 of Stock
Tempus AI Chief Accounting Officer Sells $529,650 of Stock
TEM

Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
TEM

3 Analysts, 3 Trades to Make Today
3 Analysts, 3 Trades to Make Today
TEM
News tone: automated (AI) classification of the article's content, not a price prediction.
About Tempus AI, Inc. Class A Common Stock
AI-enabled precision-medicine company that builds a large library of clinical & molecular (genomic) data and provides tests and data/AI tools to personalize care.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Eric P. Lefkofsky J.D. | Co-Founder, CEO, President & Chairman | 1970 |
| Mr. Ryan Fukushima | Chief Executive Officer of Data & Apps | 1986 |
| Mr. James Rogers | Chief Financial Officer | 1987 |
| Mr. Erik Phelps | Executive VP and Chief Administrative & Legal Officer | 1971 |
| Mr. Andrew Polovin | Chief Legal Officer | 1974 |
| Mr. Ryan M. Bartolucci CPA | Chief Accounting Officer | 1982 |
| Mr. Shane Colley | Chief Technology Officer | — |
| Dr. Kate A. Sasser Ph.D. | Chief Scientific Officer | 1978 |
| Ms. Elizabeth Krutoholow | Vice President of Investor Relations & Competitive Intelligence | — |
| Ms. Christina Antoniou | Senior VP & Head of Corporate Development | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 18, 2026
Technical indicators
- RSI 14
- 41.50
- MACD 12/26/9
- -0.36
- EMA 9 of MACD
- 1.46
- MACD histogram
- -1.82
- SMA 50
- $67.82
- Price below SMA 50
- EMA 50
- $67.88
- Price below EMA 50
- SMA 200
- $56.79
- Price above SMA 200
- EMA 200
- $62.57
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 16, 2026. Technical data, not a recommendation.
Analyst views
13 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $50.00
- Average
- $74.54
- High
- $95.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -13.0 | +29.8 | +51.2 | +8.7 | -15.9 | +35.9 | -46.4 | |||||
| 2025 | +67.6 | -8.7 | -5.3 | +9.4 | +6.4 | +0.1 | -4.8 | +38.2 | +3.0 | +2.1 | -12.2 | -20.3 |
| 2026 | -4.1 | -9.1 | -15.2 | +18.0 | -8.2 | +9.7 | -28.8 | +36.9 | +31.5 | -15.4 |



